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Abstract
Burmeister, Rachel, M.S., May 2019

Toxicology

Prevention of Crystalline Silica-Induced Inflammation by the Anti-Malarial Hydroxychloroquine
Chairperson: Andrij Holian
Exposure to inhaled crystalline silica (cSiO2) is common in occupations where there is cutting,
milling, or grinding of cSiO2 containing material. The Occupational Safety and Health
Administration estimates that over 2 million workers may be exposed to inhaled cSiO2 in the
United States. Inhalation of cSiO2 causes acute and chronic inflammation and may lead pulmonary
diseases such as silicosis, as well as an increased risk of developing autoimmune diseases.
Unfortunately, treatment of cSiO2-induced lung diseases is limited and primarily focused on
supportive care.
Inflammation caused by cSiO2 begins when, cSiO2 particles are phagocytized by alveolar
macrophages. Interaction between the particle and lysosomal membrane results in damage to the
phagolysosomal membrane; a state known as lysosomal membrane permeability (LMP). Leakage
of lysosomal contents into the cytoplasm induces NLRP3 inflammasome activation leading to cell
death and systemic inflammation. There are currently no pharmaceutical treatments that are
directed at this mechanism of disease. Many existing pharmaceuticals become sequestered in the
lysosome through an ion-trapping mechanism, and our laboratory aims to determine if these
pharmaceuticals are capable of blocking permeabilization of the lysosomal membrane. Previously,
our laboratory has shown that the tricyclic antidepressant, imipramine, blocks inflammatory
cytokine production and toxicity in alveolar macrophages after exposure to cSiO2. The objective
of this research is to determine whether another pharmaceutical, hydroxychloroquine, prevents
cSiO2-induced toxicity by blocking LMP in alveolar macrophages. The ability to target the
mechanism responsible for initiating particle-induced inflammation may lead to potential
treatments and prevention strategies for people exposed to cSiO2.
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Chapter 1: Background and Significance
1.1 Silica Exposure
Exposure to inhaled crystalline silica particles (cSiO2) remains a significant occupational health
concern. The Occupational Safety and Health Administration (OSHA) estimates that over 2
million workers may be chronically exposed to inhaled cSiO2 in the United States alone (Bang et
al., 2015). Lung disease caused by cSiO2 inhalation was recognized as an occupational hazard as
far back as 1690 when Hippocrates observed that miners often developed difficulty breathing
(Greenberg, Waksman, & Curtis, 2007). However, it is now known that cSiO2 exposure is
associated with both pulmonary and systemic disease including pulmonary fibrosis, silicosis,
chronic inflammation, and autoimmune diseases (Pollard, 2016).

Materials containing cSiO2 are used for purposes ranging from building materials to electronic
components (IARC, 2012). Exposure is most common in occupations such as mining,
construction, and manufacturing where cSiO2 containing materials are mechanically disturbed
creating inhalable aerosolized particles less than 10 µm in size (Leung, Yu, & Chen, 2012; Pollard,
2016). While the use of control measures, including dust control and wet-milling practices, have
been successful at reducing the cases of silicosis in the United States and other developed
countries, overexposures happen regularly and low level exposures over long time-frames are
common (Bang et al., 2015; Castranova & Vallyathan, 2000). Modern technologies are also
creating new opportunities for exposure. Silica nanoparticles have become the most widely used
nanotechnology and are being used extensively for biomedical purposes (J. Wang et al., 2017). In
the developing world, cSiO2 exposure is more common due to a lack of regulation and use of
personal protection equipment. Additionally, the demographics of cSiO2 exposed populations in
1

developing countries may be markedly different from developed nations. In the United States the
majority of people employed in trades where cSiO2 exposure is likely have historically been men,
and between 2001-2010 over 95% of silicosis cases in the United States were male. In developing
countries women and children make up a significant portion of cSiO2 exposures due to the
increased likelihood of these individuals being employed in unskilled work (Brass et al., 2010;
Sharma, 2008; Tiwari, Saha, & Parikh, 2009).

Pulmonary morbidities associated with the deposition of cSiO2 in the lungs include bronchitis,
silicosis, chronic obstructive pulmonary disease, increased risk of tuberculosis infections, and
cancer. Additionally, cSiO2 exposure is associated with development of systemic diseases
including rheumatoid arthritis, scleroderma, systemic lupus erythematosus, and chronic renal
disease (Leung et al., 2012; Pollard, 2016). This research focuses on the mechanisms following
cSiO2 exposure that lead to silicosis. Silicosis is a fibrotic disease characterized by pulmonary
edema, chronic interstitial inflammation, and the development of silicotic nodules (Kawasaki,
2015). Silicosis is classified into several subtypes determined by the amount of cSiO2 inhaled and
length of exposure period. Acute silicosis, also called silicoproteinosis, occurs after exposure to
high levels of cSiO2 for a short period of time. During acute silicosis the alveolar spaces become
filled with lipid and protein rich fluid and extensive neutrophilic infiltration occurs. Patients
experience severe symptoms due to decreased gas exchange capabilities and respiratory failure
(Castranova & Vallyathan, 2000). Chronic silicosis develops after 15-20 years of low to moderate
cSiO2 exposure and is the most commonly seen form of silicosis due to occupational exposures.
An accelerated form of chronic silicosis can occur after 5-10 years of higher exposure levels
(Pollard, 2016).
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After inhalation, cSiO2 particles small enough to enter deep into the lung reach the alveolar spaces;
however, cellular mechanisms for clearing debris from the alveolar spaces are ineffective at
removing cSiO2 particles. When the resident alveolar macrophages (AM) attempt to phagocytize
and clear the particles, the cSiO2 causes caspase-1 dependent pyroptosis of the AM (Bergsbaken,
Fink, & Cookson, 2009). This propagates a chronic inflammatory response as subsequent AM
ingest the particles and continue a cycle of cell death. The damaged cells release damageassociated molecular patterns (DAMPs) and inflammatory cytokines such as TNF-α, IL-1b, and
IL-6 recruiting other inflammatory cells, primarily other macrophages and polymorphonuclear
neutrophils, and stimulating fibrogenic processes (Beamer & Holian, 2007; Kawasaki, 2015;
Pollard, 2016; Rimal, Greenberg, & Rom, 2005). Fibroblasts surround the cSiO2 particles with
collagen creating fibrotic nodules which increase in size as disease progresses. The nodules can
become necrotic and massive fibrosis develops throughout the lungs. The resulting damage can be
severe and compromise pulmonary function (Rimal et al., 2005).

1.2 The NLRP3 Inflammasome and Lysosomal Membrane Permeability
Inflammation induced by cSiO2 is directed by the NLRP3 inflammasome which drives the
production of the inflammatory cytokines IL-1b and IL-18 (Jo, Kim, Shin, & Sasakawa, 2016;
Sayan & Mossman, 2016). Two signals are required for the induction of the NLRP3 inflammasome
(Fig. 1). The first signal is a priming signal which upregulates expression of the NLRP3
components. It is dependent on activation of the NF-kB pathway through TLR signaling due to
various pathogen-associated molecular patterns (PAMPs) or damage-associated molecular
patterns (DAMPs) (Biswas, Hamilton, & Holian, 2014; Sayan & Mossman, 2016). The
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translocation of NF-kB to the nucleus also increases transcription of pro-IL-1b and pro-IL-18. A
second signal induces the assembly of the NLRP3 inflammasome into the multi-protein complex
containing the apoptosis-associated speck-like protein (ASC) which binds to procaspase-1.
Procaspase-1 is cleaved into an active form and in turn cleaves pro-IL-1b and pro-IL-18 into their
mature, secreted forms (Hornung et al., 2008). Together, the first signal and the second signal
induce an inflammatory cascade and ultimately cell death (Bunderson-Schelvan et al., 2016).

There are several mechanisms proposed to initiate the second signal. These include potassium
efflux, mitochondrial damage, reactive oxygen species production, and lysosomal injury; however,
the primary mechanism of cSiO2-produced NLRP3 induction is thought to be lysosomal injury (Jo
et al., 2016). When cSiO2 particles are phagocytized by AM, they interact with the interior of the
phagolysosomal membrane and cause disruption to the membrane. This is referred to as lysosomal
membrane permeability (LMP) (Bunderson-Schelvan et al., 2016; Serrano-Puebla & Boya, 2016).
The compromised lysosomal membrane allows the acidic hydrolases, including cathepsin B,
normally contained by the lysosome to leak into the cytosol (P Boya & Kroemer, 2008). There are
currently no pharmaceuticals that target a molecular mechanism of cSiO2 toxicity to reverse or
prevent silicosis; however, targeting the lysosome in order to block LMP could be a promising
way to diminish cSiO2 toxicity (Biswas et al., 2017).

4

Figure 1: Proposed model of LMP
Model of the inflammatory cascade following particle-induced lysosomal membrane permeability.
(Bunderson-Schelvan et al., 2016)

1.3 Cationic Amphiphilic Drugs
Many existing pharmaceuticals are known to interact with and become sequestered in the
lysosome. This primarily occurs in a class of drugs known as cationic amphiphilic drugs (CAD).
CAD tend to be weak bases that easily diffuse through membranes in their unprotonated state.
Once they have diffused into the lysosome, they become protonated in the acidic environment
subsequently preventing them from diffusing out of the lysosome. This ion-trapping mechanism
results in a high concentration of drug stored within the lysosome (Villamil Giraldo et al., 2014).
While this is considered an off-target effect for many drugs, this action may provide an opportunity
to prevent particle-induced damage. Previously, our laboratory has shown that one CAD,
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imipramine (IMP), can reduce pulmonary inflammation after exposure to cSiO2 both in vivo and
in vitro (Biswas et al., 2017). IMP is a tricyclic antidepressant that has been shown to have some
protective effects against lung injury (Yang et al., 2010). Interestingly, another CAD,
hydroxychloroquine (HCQ) is commonly used in the treatment of the autoimmune disease
systemic lupus erythematosus (Fig. 2). Exposure to cSiO2 has been shown to contribute to the
development of systemic lupus erythematosus; however there has been no research examining the
effect of HCQ on cSiO2-induced toxicity.

HCQ has been extensively used to prevent malaria and as treatment for autoimmune diseases such
as rheumatoid arthritis and systemic lupus erythematosus (Olsen, Schleich, & Karp, 2013).
Recently HCQ has been investigated for use in diseases including endometriosis, cancer,
cardiovascular disorders, diabetes, and infectious diseases (Ben-Zvi, Kivity, Langevitz, &
Shoenfeld, 2012; D. Chen et al., 2018; Ruiz et al., 2016). There are many proposed mechanisms
to explain how HCQ could be acting in such a diverse number of diseases. Some evidence has
shown that HCQ can reduce inflammatory cytokine production by macrophages and alter
macrophage phenotype (D. Chen et al., 2018). Other reports show changes in B and T cell signaling
and inhibition of phospholipase A2 (Ben-Zvi et al., 2012). HCQ’s effect on cancer and
endometriosis have been attributed to modulation of autophagy. Furthermore, in a murine model
of endotoxic shock, Chen et al. showed that chloroquine can decrease activation of the NLRP3
inflammasome and block production of IL-1b and IL-18 (D. Chen et al., 2018). However, no work
has been done to examine whether HCQ accomplishes this by preventing destabilization of the
lysosomal membrane nor if HCQ can prevent cSiO2-induced LMP.
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Figure 2: Chemical structure of HCQ
IUPAC name 2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol

1.4 Specific Aims
The objective of this research was to determine if HCQ reduces cSiO2 toxicity in alveolar
macrophages. There are currently no pharmaceuticals that target a molecular mechanism of cSiO2
toxicity to reverse or prevent silicosis; however, targeting the lysosome in order to block LMP
could be a promising way to diminish cSiO2 toxicity (Biswas et al., 2017). The objective of this
research is to determine if HCQ has the ability to attenuate pulmonary cSiO2 toxicity. My
hypothesis is that HCQ blocks LMP and decreases cSiO2-induced inflammation in alveolar
macrophages.

Specific Aim 1: Determine that cSiO2-induced toxicity is blocked by hydroxychloroquine in
vitro.

Hypothesis: LMP will be decreased in HCQ treated alveolar macrophages which are exposed to
cSiO2 particles in vitro. In vitro studies will be conducted in order to show that HCQ can prevent
LMP after cSiO2 exposure. These studies will be conducted in bone marrow derived macrophages
7

(BMDM) from C57Bl/6 mice. LMP will be assessed through a digitonin assay measuring β-Nacetylglucosaminidase release. Additionally, inflammasome activation, toxicity, and cytokine
production will be measured.

Methods:
Toxicity Assays
Using C57Bl/6 BMDM, I will show that HCQ blocks cSiO2-induced toxicity. BMDM will be
exposed to various doses (0-50 µg/mL) of cSiO2. Toxicity will be analyzed with a common
tetrazolium viability (MTS) assay (Promega, cat. G3580) and the lactate dehydrogenase assay
(Promega, cat. G1780). NLRP3 inflammasome activation will be confirmed by assaying the
release of IL-1b (R&D Systems, cat. DY201).
Measures of LMP
•

In order to determine if HCQ can reduce LMP caused by cSiO2, LMP will be quantified
through measurement of released a-N-acetylglucosaminidase after digitonin extraction
based on Aits et al., 2015, as previously described by our laboratory (Aits, Jäättelä, &
Nylandsted, 2015; Jessop, Hamilton, Rhoderick, Shaw, & Holian, 2016)

•

Alternative methods of assessing LMP using Lysotracker dyes will also be used.

Phagocytosis
To ensure that LMP is not being altered due to differences in phagocytosis after being
treated with HCQ, the relative amount of particle phagocytized by macrophages will be
assessed by measuring relative side-scatter by flow cytometry of untreated macrophages
and those treated with HCQ.
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Specific Aim 2: Establish that HCQ prophylactically reduces cSiO2-induced inflammation
in a murine model of acute silicosis.

Hypothesis: Mice treated with HCQ before cSiO2 treatment will show reduced toxicity after acute
cSiO2 exposure. C57Bl/6 mice will be treated with HCQ by oral gavage (to simulate normal
pharmaceutical administration of HCQ by patients) for 7 days prior to oropharyngeal instillation
of cSiO2. Twenty-four hours after cSiO2 exposure mice will be sacrificed. Inflammatory cytokines,
cathepsin release, and toxicity will be assessed.

Methods: Mice will be treated with HCQ (10 mg/kg) through oral gavage once per day for a
duration of seven days. Mice will then be exposed to cSiO2 (0.25 mg or 1 mg) by oropharyngeal
instillation and sacrificed 24 hours after exposure. Whole lung lavage fluid will be collected and
assayed for cathepsin release as a measure of LMP. Lavage fluid will be assessed for protein,
inflammatory cytokines (IL-1b, TNF-a, IL-6, IL-18, IL-33), cytotoxicity, and infiltration of
immune cells.

9

Chapter 2: Methods
2.1 Mice
C57Bl/6 mice (Jackson Laboratories, Bar Harbor, ME) were housed in the University of
Montana’s specific-pathogen-free Laboratory Animal Resources facility. The mouse room is
maintained on a 12 hr light/dark cycle and mice were provided with mouse feed and deionized
water ad libitum. Male and female mice between 8-16 weeks of age were used for the studies.
Euthanasia was administered through intraperitoneal injection of a lethal dose of pentobarbital
sodium (Euthasol, Virbac, Fort Worth, TX). The University of Montana Institutional Animal Care
and Use Committee (Missoula, MT, USA) approved all procedures performed on the animals.
2.2 Crystalline Silica
Crystalline silica (Min-U-Sil-5, average particle size 1.5-2 µm in diameter) was obtained from
Pennsylvania Sand Glass Corporation (Pittsburgh, PA), and acid washed in 1N HCl. The cSiO2
was washed with sterile water four times and dried in an oven at 200°C. Before use, cSiO2 particles
were suspended in PBS or dispersion media (for in vivo experiments) and sonicated for at least 2
min (550 watts at 20 kHz) by a cup-horn sonicator in a circulating water bath (Misonix, Inc.
Farmingdale, NY, USA). Dispersion media consisted of PBS containing 0.6 mg/ml mouse serum
albumin and 0.01 mg/ml 1,2-dipalmitoyl-sn-glycero-3-phosphocholine.
2.3 Isolation and Culture of Bone Marrow Derived Macrophages
Bone Marrow Derived Macrophages (BMDM) were generated as described previously
(Migliaccio, Buford, Jessop, & Holian, 2008; Pfau et al., 2004). C57Bl/6 mice were sacrificed and
the hind legs were removed. Complete media (RPMI, 10% FBS, Penicillin/Streptomycin) was
washed through the femur and tibia to collect the bone marrow cells. Cells were incubated in T75
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flasks at a density of 3.0x107 overnight at 37°C for stromal elimination by adherence. The next
day, nonadherent cells are transferred to a new flask at a density of 1.5x107 cells per flask.
Macrophage colony stimulating factor (M-CSF) (20 ng/mL R&D Systems) was added and cells
were spiked with M-CSF (10 ng/ml R&D Systems) every 3-4 days. BMDM were used on day 10.
2.4 In Vitro Toxicity Assays
BMDM were platted in a flat-bottom, tissue culture- treated 96-well plates at 1×105 cells/well in
100 µL of RPMI complete media and incubated with lipopolysaccharides (LPS) (20 ng/mL) for
inflammasome priming. Cells were treated with 25 µM of hydroxychloroquine sulfate (SigmaAldrich cat. H0915-5MG), 25 µM imipramine hydrochloride (Sigma-Aldrich cat. 10899-5G), or
100 nM bafilomycin (EnzoLife Sciences cat. BML-CM110-0100) for 30 minutes prior to addition
of cSiO2. Cells were exposed to various doses (0-50 µg/mL) of cSiO2 and plates were incubated
in a 37°C water-jacketed CO2 incubator (ThermoForma, Houston, TX) for 24 hours. Toxicity
induced by cSiO2 was determined by two complementary assays, a lactate dehydrogenase assay
(Promega, cat. G1780) and a common colorimetric tetrazolium viability (MTS) assay (Promega,
cat. G3580), and read on a plate reader (Molecular Devices SpectraMax M4 colorimetric
microplate reader). In order to avoid artifacts in the optical density values, the MTS reaction was
transferred to a clean plate to separate it from the cell/particle mixture adhered to the plate bottom.
Data were normalized to a percent relative to the no particle, no HCQ control cells. NLRP3
inflammasome activation was assayed by measuring the release of IL-1β by using a commercially
available ELISA kit (R&D Systems, cat. DY201).
2.5 In Vivo Treatments
C57Bl/6 mice were treated with either hydroxychloroquine (Hydroxychloroquine Sulfate,
Calbiochem cat. 509272) reconstituted in PBS (10 mg HCQ/kg/per day) or vehicle (PBS) by oral
11

gavage once a day for seven days. After the seven days, mice were instilled with 1 mg or 0.25 mg
of cSiO2 through oropharyngeal aspiration. Prior to gavage and instillation of cSiO2, mice were
briefly anesthetized by isoflurane. For instillation, the sedated mouse is positioned vertically while
50 µL of dispersion media with or without cSiO2 was dispensed with a pipette to the back of the
throat. By holding the tongue to the side, the mouse could not swallow and, therefore, aspirated
the volume into the lungs. Mice were sacrificed 24 hours after cSiO2 exposure for analysis by
collecting whole lung lavage fluid. The lungs and heart were removed from the chest cavity, and
1 mL of cold PBS was washed in and out of the lungs four times in order to collect concentrated
lung fluid. Samples were centrifuged at 400 x g for 5 minutes and the supernatant was saved for
analysis. The lungs were lavaged with an additional 4 mL of PBS in order to collect the maximum
number of cells. Lavage cells were counted using a Coulter Z2 particle counter (Beckman Coulter,
Brea, CA, USA) and resuspended in RPMI 1640 culture media supplemented with 10% fetal
bovine serum, sodium pyruvate, and an antibiotic-antimycotic solution (Mediatech, Manassas,
VA) for differential analysis or flow cytometry. Cells were stained for differential analysis with a
Wright-Geimsa stain in a Hematek 2000 autostainer (Miles-Bayer-Siemens Diagnostics,
Deerfield, IL, USA).
2.6 In Vivo Lung Injury and Inflammation Assays
Toxicity was measured in the lung lavage fluid by assaying for LDH as above. Cytokines from
lung lavage fluid were measured by a multiplex immunoassay (MSD U-PLEX, Meso Scale
Diagnostics, U-PLEX, cat K15069L-2) because of the sensitivity and small sample size used.
Seven cytokines IFN-g, IL-1b, IL-6, IL-10, IL-13, IL-33, and TNF-a were included in the 7-plex
plate used for this experiment. Protein in the lung lavage fluid was assayed by the Pierce BCA
Protein Assay Kit (ThermoFisher Scientific cat. 23225) following manufacturers specifications.
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Extracellular cathepsin B release in the lavage fluid was analyzed as previously described by our
laboratory (Sager et al., 2016). In a 96 well plate, 50 µL of whole lung lavage was combined with
50 µL of a cathepsin B inhibitor (Calbiochem cat. 219385) or 50 µL PBS and incubated at room
temperature for 15 min. Then the cathepsin substrate Z-LR-AMC (specific to cathepsin B,
cathepsin L and cathepsin V; R&D systems cat. ES008) at 20 µL in PBS was added to 50 µL of
whole lung lavage fluid in a total reaction volume of 150 µL. The assays were incubated at 37°C
for 1 hour then fluorescence was measured using a plate reader at 380 nm excitation and 460 nm
emission. The wells with the only the cathepsin substrate measured the total (cathepsin B,
cathepsin L and cathepsin V) cathepsin activity in the lavage fluid while wells with the cathepsin
B inhibitor measured the remaining cathepsin L and cathepsin V activity. By subtracting the
inhibitor wells from the total cathepsin well, the level of cathepsin B was calculated.
2.7 Ex Vivo Culture for IL-1b Production
Cells collected during the whole lung lavage of mice treated with 0.25 mg of cSiO2 in vivo were
plated for ex vivo IL-1b culture. Lung lavage fluid was centrifuged and the supernatants saved for
other analyses. Cells were resuspended in 250 µL of complete media, counted, and then 100 µL of
cell suspension was plated in a 96 well plate. Cells were primed for inflammasome activity with
LPS (20 ng/mL) and incubated for 24 hours at 37°C. After incubation, supernatants were collected
and assayed with a commercial IL-1b kit (R&D Systems, cat. DY201). Data were normalized to
IL-1b release per 1x105 AM using the total cell count and percent of macrophages in the whole
lung lavage.
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2.8 Flow Cytometry
Flow cytometry was used to assess phagocytosis of cSiO2 particles and lysosomal uptake of
LysoTracker dye both in BMDM and AM collected in the lung lavage of treated mice.
Internalization of cSiO2 was determined by using a side-scatter technique previously described
(Hamilton, Thakur, Mayfair, & Holian, 2006). BMDM or lung lavage cells were cultured or
collected as described above. BMDM were treated with 25 µM HCQ for 30 minutes and then
exposed to 50 µg/mL cSiO2 for 4 hours using 1.5 mL microfuge tubes and end over end tumbling
(Lab Quaker Shaker, Thermo Forma). Lung lavage cells had no additional treatment of HCQ or
cSiO2 after the in vivo exposures.

Both lung lavage cells and BMDM were treated with

LysoTracker Red DND-99 (ex/em 577⁄590 nm, ThermoFisher Scientific cat. L7528) at 50 nM for
30 min. The cells were centrifuged, resuspended in PAB, and transferred to filter-top flow
cytometry tubes (BD Biosciences, San Jose, CA) for analysis. Phagocytosis and LysoTracker
uptake data were expressed as mean fluorescent intensity. Cells were analyzed on a Life
Technologies Attune NxT Acoustic Focusing Cytometer with the YL-1 585/16 nm laser.
2.9 Lysosome Membrane Permeabilization Assay
Lysosome membrane permeabilization (LMP) was assessed using methods modified from Aits et
al. (Aits et al., 2015) and as described previously by our laboratory (Jessop, Hamilton, Rhoderick,
Fletcher, & Holian, 2017). BMDM were plated in 24 well plates at a density of 2×105 cells per
well. Cells were treated with or without HCQ (25 µM) and with or without cSiO2 (50 µg/mL).
Cells were washed twice with PBS and placed on ice. BMDM were then incubated with 200 µL
of cytosol extraction buffer, which consisted of 250 mM sucrose, 20 mM Hepes, 10 mM KCl, 1.5
mM MgCl2, 1 mM EDTA, 1 mM EGTA, 0.5 mM pefabloc (Sigma-Aldrich cat. 76307-100mg),
pH 7.5, and digitonin (15 µg/mL ) (Sigma-Aldrich cat. D141-100MG), for 15 min on ice with
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rocking. The concentration of digitonin for optimal extraction of the cytosolic fraction was
determined by titration. β-N-acetylglucosaminidase (NAG) activity was measured by adding 30
µL cytosolic extract to 100 µL of NAG reaction buffer (0.2 M sodium citrate, pH 4.5 with 300
µg/mL 4-methylumbelliferyl-2-acetamido-2-deoxy-β-D-glucopyranoside (Sigma-Aldrich cat.
37067-30-4) and assessed on a plate reader (20 min; 45s intervals; 356 nm excitation; 444 nm
emission). Extracted cytosolic LDH activity was measured as described above and used as a
control to which the NAG activities were normalized.

2.10 Statistical Analysis
Depending on the data type, a parametric one or two-way analysis of variance (ANOVA), followed
by post hoc mean comparison (Holms-Sidak etc.) was used throughout the research described.
Statistical significance will be defined as a two-tailed probability of type I error at less than 5% (p
< 0.05) unless otherwise stated. The minimum number of experimental replications was 3.
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Chapter 3: Results
3.1 HCQ decreases cSiO2 toxicity in vitro
The ability of HCQ to decrease toxicity and cell death in vitro was assessed using C57Bl/6 BMDM.
BMDM were primed for inflammasome activation with LPS (20 ng/mL) and then treated with
either HCQ (25 µM), imipramine (IMP, 25 µM), or bafilomycin A1 (BAF, 100 nM) for 30 min
prior to cSiO2 exposure. IMP and BAF were positive controls for blocking cSiO2-induced toxicity.
Bafilomycin A1 (BAF) specifically inhibits vATPases to prevent lysosomal acidification, which
previous studies have indicated is necessary for particle induced toxicity (Jessop et al., 2017). In
biological systems small particles develop a protein shell called a protein corona. The protein
corona is degraded in the acidic environment of the lysosomes which allows the particle to directly
interact with the lipid membrane causing LMP. Preventing acidification is thought to prevent
degradation of the protein corona and protect the lysosome from LMP (F. Wang et al., 2013).
Imipramine, a tricyclic anti-depressant, was previously shown by our laboratory to block cSiO2induced toxicity; therefore, it was used as a comparison to HCQ (Biswas et al., 2017).

Cells were exposed to 0, 50, or 100 µg/mL of cSiO2 and incubated for 24 hrs at 37° C. HCQ, IMP,
and BAF were all found to block toxicity at both the 50 µg/mL and 100 µg/mL exposures of cSiO2
as determined by the LDH assay and MTS assay (Fig. 3). No toxic effect from either HCQ or IMP
alone was found in cells not exposed to cSiO2. Protective effects were more pronounced at the 50
µg/mL cSiO2 exposure as there was significant cell death at the 100 µg/mL cSiO2 dose which could
not be completely overcome by the HCQ, IMP, or BAF. Cell supernatants were assayed for IL-1β
as a representative measure for NLRP3 inflammasome activation. IL-1β production was drastically
decreased in exposed cells receiving HCQ, IMP, and BAF (Fig. 4).
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Figure 3: HCQ decreases cSiO2-induced toxicity in BMDM.
BMDM were treated with HCQ (25 µM), IMP (25 µM), or bafilomycin A1 (100 nM) and exposed
to 0, 50, or 100 µg/mL of cSiO2. HCQ, IMP, and BAF caused statistically significant decrease in
cSiO2 toxicity as determined by decreased LDH release and increased cell viability.
(**** p < 0.0001, ** p < 0.01, * p < 0.05) n = 3-4
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Figure 4: HCQ blocks the production of IL-1b in BMDM exposed to cSiO2.
Cell supernatants were assayed for IL-1β as a representative measure for NLRP3 inflammasome
activation. IL-1β production was blocked in exposed BMDM treated with HCQ (25 µM), IMP (25
µM), or bafilomycin A1 (100 nM) at both 50 (** p < 0.01) and 100 µg/mL (**** p < 0.0001) cSiO2
exposures. Symbols indicate significance between control and treated cells. n = 3-4
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3.2 HCQ does not affect cSiO2 uptake in vitro
In order to confirm that HCQ was not blocking cSiO2 toxicity by reducing phagocytosis of the
cSiO2 particles, the amount of cSiO2 taken up by the BMDM was quantified by flow cytometry
(Fig. 5). BMDM which have taken up cSiO2 into their phagolysosomes have higher side-scatter
(SSC) due to the deflection of laser light by the cSiO2 particles. BMDM exposed to cSiO2 (50
µg/mL) with or without HCQ (25 µM) had significantly higher side scatter (****p < 0.0001) than
BMDM not exposed to cSiO2. There was no difference between the SSC of control vs HCQ-treated
cells nor cSiO2 vs HCQ + cSiO2 cells. This indicates that HCQ does not affect the ability of BMDM
to take up cSiO2.

Additionally, BMDM were also treated with LysoTracker Red DND-99 at 50 nM for 30 min (as
per manufacturers recommendations) to assess the relative acidity of the lysosomes (Fig. 6). HCQ
treatment caused a decrease in the amount of LysoTracker taken up by lysosomes. This finding
suggests that HCQ is present in the lysosomes and may cause lysosomes to be less acidic. In turn,
this may help protect the lysosomes from being permeabilized by cSiO2. Cells treated with HCQ
or HCQ + cSiO2 had significantly less (*p < 0.05) LysoTracker uptake than control cells or cells
exposed cSiO2 without HCQ treatment. Together, the in vitro results collected in these experiments
are consistent with HCQ being able to reduce LMP after cSiO2 exposure.
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Figure 5: HCQ does not affect uptake of cSiO2 in vitro.
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Figure 6: HCQ reduces the uptake of LysoTracker in vitro.
BMDM were treated with LysoTracker Red DND-99 at 50 nM for 30 min to assess the relative
acidity of the lysosomes. HCQ treated cells showed less uptake of LysoTracker. Cells exposed to
cSiO2 without HCQ treatment had significantly (*p < 0.05) more LysoTracker uptake than cells
exposed to cSiO2 and treated with HCQ. n = 3
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3.3 HCQ blocks LMP in vitro
Direct quantification of the ability of HCQ to block LMP in vitro was assessed through a method
modified from Aits et al. which measures the release of β-N-acetyl-glucosaminidase (NAG) into
the cytosol after cell permeabilization by the detergent digitonin (Aits et al., 2015). NAG is a
lysosomal hydrolase which is not present in the cytosol unless the lysosomal membrane has been
compromised. Using BMDM the level of digitonin is titrated so that the cell membrane is
permeabilized while the lysosomal membrane remains intact. The lysosomal membrane contains
less cholesterol than the cell membrane making the digitonin required to permeabilize the
lysosomal membrane higher than that required for the cell membrane (Aits et al., 2015). BMDM
were treated with or without HCQ (25 µM) and with or without cSiO2 (50 µg/mL) and incubated
for 4 or 24 hours. Cytosolic LDH activity was measured as described above and used as a control
to which the NAG activities were normalized. HCQ was able to significantly block the release of
NAG from lysosomes after both 4 (*p < 0.05) and 24 (***p < 0.001) hours. This shows that HCQ
blocks cSiO2-induced LMP in vitro.
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Figure 7: HCQ
blocks LMP in vitro.

cSiO2 from HCQ + cSiO2 ***p < 0.001, n = 3

BMDM were treated with or without HCQ (25 µM) and with or without cSiO2 (50 µg/mL) and
incubated for 4 or 24 hours. HCQ was able to significantly block the release of NAG from
lysosomes after both 4 (*p < 0.05) and 24 (***p < 0.001) hour cSiO2 exposures. n = 3
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3.4 Evaluation of HCQ on cSiO2 uptake in vivo
The above in vitro studies demonstrated that HCQ accumulated in macrophages and blocked the
ability of cSiO2 to cause LMP and downstream events including toxicity and NLRP3
inflammasome activation as determined by IL-1b release. However, in vivo studies have not been
previously conducted in order to determine whether the in vitro studies predict in vivo outcomes.
Therefore, C57Bl/6 mice were treated with HCQ at 10 mg/kg/day or PBS by oral gavage for 7
days. This dose of HCQ was chosen based on previous in vivo studies with HCQ (X. Chen et al.,
2017; Gómez-Guzmán et al., 2014). At the end of the 7-day pre-treatment period, mice were
exposed to either 0.25 mg or 1 mg of cSiO2 by oropharyngeal instillation (in 50 µL of dispersion
media). Control mice received only dispersion media. Mice were sacrificed 24 hours post cSiO2
exposure. The 1 mg of cSiO2 exposure, has been commonly used in previous studies allowing
comparison to previous results (Biswas et al., 2017). A lower dose of 0.25 mg was also evaluated.
Naïve mice generally have around 3-4x105 AM residing in their lungs. Therefore, the 0.25 mg
dosage more closely matches the in vitro dose used in this study of 50 µg/mL cSiO2 per 1x105
BMDM.

In order to investigate whether HCQ was incorporated into the AM during the 7-day HCQ in vivo
treatment, AM from whole lung lavage were treated with LysoTracker Red DND-99 and the cells
analyzed by flow cytometry. As in the in vitro experiments, AM from mice treated with HCQ
showed significantly less uptake of the LysoTracker dye. This finding suggests that in mice treated
with HCQ at 10 mg/kg by oral gavage for 7 days did have HCQ sequestered into lysosomes of the
AM (Fig. 8). Additionally, in order to rule out that HCQ was reducing toxicity due to changes in
cSiO2 uptake by the AM in vivo, side scatter data of the whole lung lavage cells were collected by
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flow cytometry. Side scatter was increased as expected in the cSiO2-treated mice and there was no
difference between the control and HCQ-treated mice nor the cSiO2 and HCQ + cSiO2-treated
mice. This matches the in vitro data showing that changes in cSiO2-induced toxicity in HCQtreated mice is not due to a change in the ability of the AM to phagocytize the cSiO2 (Fig. 9).
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Figure 8: HCQ accumulates in lysosomes of AM after treatment by oral gavage.
AM from whole lung lavage of control or HCQ treated C57Bl/6 mice were incubated with
LysoTracker Red DND-99 for 30 minutes prior to analysis by flow cytometry. In AM from mice
treated with HCQ, there was significantly less uptake of the LysoTracker dye (*p < 0.05). This
result is consistent with HCQ being sequestered into the lysosomes of the AM in vivo. n = 4
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Figure 9: HCQ does not affect phagocytosis of cSiO2 by AM in vivo
Whole lung lavage cells from mice treated in vivo ± HCQ and ± cSiO2. Side scatter was increased
as expected in the cSiO2-treated mice. There was no difference between the control and HCQtreated mice nor the cSiO2 and HCQ + cSiO2-treated mice suggesting that a difference in the uptake
of cSiO2 was not contributing to changes in toxicity. n = 4
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3.5 Evaluation of HCQ on cSiO2-induced inflammation and toxicity in vivo

Instillation of cSiO2 is known to cause lung inflammation and infiltration of immune cells.
Therefore, differential cells counts were conducted on the whole lung lavage fluid (Fig. 10). At
the 1 mg cSiO2 dose, there were no differences in the percentage of cells or the raw cell numbers
between the HCQ treated mice and control mice ± cSiO2 exposure. Mice exposed to cSiO2
displayed the expected neutrophilic infiltration. At the 0.25 mg cSiO2 dose, cSiO2-exposed mice
which were treated with HCQ had a significant increase in the percentage of macrophages and a
significant decrease in the percentage of neutrophils recruited to the lungs as compared to cSiO2
exposed mice with no HCQ treatment. Additionally, cSiO2-exposed mice with HCQ treatment had
a greater number of macrophages in their lungs 24 hours after cSiO2 exposure than did cSiO2
exposed mice without HCQ treatment. This suggests that macrophages may be protected from
cSiO2 induced pyroptosis with HCQ treatment.

In order to evaluate lung injury following instillation of cSiO2, lavage supernatants were assayed
for LDH release, total protein (bicinchoninic acid assay, BCA), relative total cathepsin, and
relative cathepsin B levels (Fig. 11). Although not significant, LDH, total cathepsin, and cathepsin
B release were all lower in HCQ treated mice at both the 0.25 mg and 1 mg cSiO2 exposures. Total
area under the LDH curves for control and HCQ treated mice were 241.3 ± 100.6 and 165.1 ±
52.58 respectively (Table 1). Surprisingly, LDH appeared to be higher in the 0.25 mg cSiO2
exposed mice than the 1 mg cSiO2 exposed mice, relative to control mice. While data were
normalized to control mice, the 0.25 mg cSiO2 exposure and the 1 mg cSiO2 experiments were
conducted at different times and the LDH assays run on different days which could account for
this apparent discrepancy. Total protein in the lung lavage supernatants, as measured by a BCA
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assay, was used to assess lung injury. The BCA assay showed a slight decrease in the amount of
protein in the lung lavage fluid at the 1 mg cSiO2 dose in HCQ-treated animals versus control. As
expected the lung protein level increased as the cSiO2 dose increased in both control and HCQtreated mice.
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Figure 10: HCQ-treated mice retain more AM and have less infiltration of neutrophils.
Differential cell counts for 0.25 mg and 1 mg cSiO2 treated mice. At 1 mg of cSiO2, there were no
differences in the percentage of cells or the raw cell numbers between the HCQ-treated mice and
control mice ± cSiO2 exposure. Mice exposed to cSiO2 showed neutrophilic infiltration. At the
0.25 mg cSiO2 dose, HCQ + cSiO2 mice had a significant increase in the percentage of
macrophages (*p < 0.05) and a significant decrease in the percentage of neutrophils (**p < 0.01)
as compared to cSiO2-exposed mice with no HCQ treatment. HCQ + cSiO2 mice had significantly
more macrophages in their lungs 24 hours after cSiO2 exposure than did cSiO2-exposed mice
without HCQ treatment (*p < 0.05). n = 4-5

29

BCA

LDH Release
(Relative to Control)

150

Protein Concentration
(µg/mL)

LDH
Control
HCQ
100

50

0

0

0.25

1000

Control

800

HCQ

600
400
200
0

1

0.0

1.0

Cathepsin B

Total Cathepsin
600

Control
HCQ

400

200

80

Cathepsin B (RFU)

Total Cathepsin (RFU)

0.5

cSiO2 Dose (mg)

cSiO2 Dose (mg)

Control
HCQ

60
40
20
0

0
0.0

0.5

1.0

0.0

cSiO2 Dose (mg)

0.5

1.0

cSiO2 Dose (mg)

Figure 11: HCQ reduces cSiO2 toxicity in vivo
LDH, total cathepsin, and cathepsin B release were lower in HCQ-treated mice at both 0.25 mg
and 1 mg cSiO2 exposures. The BCA assay showed a slight decrease in the amount of protein in
the lung lavage fluid at the 1 mg cSiO2 dose in HCQ-treated animals versus control. As expected
the protein level increased as the cSiO2 dose increased in both control and HCQ-treated mice.
n = 4-5.

Table 1: Total Area Under the Curve for LDH Release
Total Area Under the Curve for LDH Release
Total Area

Control

HCQ Treated

241.3 ± 100.6

165.1 ± 52.58
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3.6 In vivo cytokine production after HCQ treatment.

Cytokines from lung lavage supernatants were measured by a multiplex immunoassay (MSD UPLEX, Meso Scale Diagnostics) because of the sensitivity and small sample size used (Figs. 12
and 13). Seven cytokines IFN-g, IL-1b, IL-6, IL-10, IL-13, IL-33, and TNF-a were included in
the 7-plex plate used for this experiment. IL-10 and IL-13 levels were below detection levels for
both 0.25 mg and 1 mg cSiO2-exposures and were not graphed. For mice exposed to 1 mg of cSiO2,
IFN-g was only detectable in the cSiO2 exposed group suggesting that HCQ was able to reduce
IFN-g after cSiO2 exposure (*p < 0.05). While not significant, there was a trend that IL-6, IL-33,
and TNF-a appeared to be lower with HCQ treatment in the 1 mg cSiO2 exposed mice. IL-1b did
not appear to be blocked with HCQ treatment. For the 0.25 mg dose, IFN-g again appeared to be
decreased by HCQ treatment, although in this case it was not statistically significant due to a large
variance in the cSiO2-exposed group. As in the 1 mg dose group, there is was a trend that HCQ +
cSiO2 mice seem to have lower levels of TNF-a as compared to cSiO2 only mice. In all graphs, no
visible bar signifies that levels were below detection.
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Figure 12: Cytokines after 1 mg SiO2 exposure
Cytokines from lung lavage supernatants measured by a multiplex immunoassay. IFN-g was only
detectable in the cSiO2-exposed group suggesting that HCQ was able to block IFN-g after cSiO2
exposure (*p < 0.05). While not significant, the data suggest a trend toward HCQ decreasing
production of IL-6, IL-33, and TNF-a. IL-1b did not appear to be blocked with HCQ treatment.
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Figure 13: Cytokines after 0.25 mg SiO2 exposure
For the 0.25 mg dose, IFN-g appeared to be decreased by HCQ treatment, though not statistically
significant due to a large variance in the cSiO2-exposed group. As in the 1 mg dose group, there is
a trend that HCQ + cSiO2 mice seem to have lower levels of TNF-a as compared to cSiO2 only
mice. n = 4-5
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3.7 HCQ blocks IL-1b production in ex vivo culture
Since HCQ was effective in blocking silica-induced IL-1b release from AM and the data showed
that HCQ was taken up by lysosomes in AM, the AM from the mice were evaluated ex vivo. Cells
collected during the whole lung lavage of mice treated with 0.25 mg of cSiO2 in vivo were plated
for ex vivo IL-1b culture and primed with LPS. After incubation, supernatants were assayed for
IL-1b by ELISA. Data were normalized to IL-1b release per 1x105 AM using the total cell count
and percent of macrophages. Control and HCQ treated cells had very little IL-1b production as
expected. Consistent with the in vitro data, cells from HCQ + cSiO2 treated mice had a significantly
less IL-1b production when compared to cSiO2 exposed mice not treated with HCQ. These data
are consistent with HCQ being able to prevent LMP after cSiO2 exposure in vivo.
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Figure 14: Ex Vivo Culture of C57Bl/6 AM
Cells collected during the whole lung lavage of mice treated with 0.25 mg of cSiO2 in vivo were
p <.05
plated for ex vivo IL-1b culture. Data were normalized to IL-1b release per 1x105 AM using the
total cell count and percent of macrophages. Control and HCQ-treated cells produced only trace
amounts of IL-1b. Cells from HCQ + cSiO2 treated mice had significantly less IL-1b production
when compared to cells from mice only exposed to cSiO2 (*p < 0.05). These data are consistent
with HCQ being able to prevent LMP after cSiO2 exposure in vivo. n = 4-6
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Chapter 4: Discussion
Silicosis is a progressive, fibrotic pulmonary disease that occurs after exposure to inhaled cSiO2.
The loss of pulmonary function resulting from silicosis causes significant morbidity and, in severe
cases, mortality. Treatment options are limited to supporting respiratory function through
supplemental oxygen and decreasing inflammation with corticosteroids (Leung et al., 2012). A
growing body of evidence suggests that a key step in cSiO2-induced lung inflammation is
activation of the NLRP3 inflammasome resulting in the release of pleiotropic cytokines such as
IL-1b and IL-18. At this time there is limited information on possible pharmaceutical approaches
to regulation of NLRP3 inflammasome activity. However, it may be possible to regulate LMP,
which has been proposed to precede NLRP3 inflammasome activation (Sayan & Mossman, 2016;
Serrano-Puebla & Boya, 2016). When cSiO2 is phagocytized by resident AM in an attempt to clear
the particles from the lungs, the cSiO2 compromises lysosomal membranes allowing lysosomal
proteases to leak into the cytosol and induce NLRP3 inflammasome assembly (P Boya & Kroemer,
2008; Bunderson-Schelvan et al., 2016; Jessop et al., 2017). Therefore, blocking LMP would
attenuate NLRP3 inflammasome assembly and could be a key mechanism to target in order to treat
cSiO2-induced inflammation. HCQ was chosen for this research because it is cationic amphiphilic
drug (CAD) that is known to accumulate in lysosomes (Ben-Zvi et al., 2012; Patricia Boya et al.,
2003). CADs diffuse through membranes in an unprotonated state but become protonated in the
acidic environment of lysosomes, losing their ability to diffuse back out through lipid membranes.
HCQ is used extensively as an anti-malarial and also to treat autoimmune diseases such as systemic
lupus erythematosus (SLE). However, the precise mechanism to explain its action in SLE is
unclear (Ben-Zvi et al., 2012).
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The in vitro work from this study strongly supports the hypothesis that HCQ is able to block cSiO2induced LMP. HCQ was able to rescue BMDM from cell death after exposure to 50 or 100 µg/mL
of cSiO2 (Fig. 3). HCQ also caused significant reduction in the production of IL-1β in BMDM
after cSiO2 exposure (Fig. 4). These data are consistent with a 2017 paper by Chen et al. where
they found that chloroquine (which differs from HCQ by one hydroxyl group) suppresses NLRP3
inflammasome activation in a murine model of endotoxic shock (X. Chen et al., 2017). Chen et al.
showed that chloroquine is able to decrease IL-1β and IL-18 release from BMDM stimulated with
LPS. They also found that chloroquine inhibits transcription of Nlrp3 genes. Their research,
however, did not examine the effect of HCQ on cSiO2-induced toxicity.

Our research also directly measured the ability of HCQ to prevent LMP by measuring the release
of β-N-acetyl-glucosaminidase (NAG) into the cytosol. HCQ was able to block NAG release in
BMDM exposed to cSiO2 at both 4 and 24 hours (Fig. 5). This data conflicts with data published
by Boya et al. in 2003 where they argue that HCQ induces LMP. When cells were stained by
immunofluorescence for cathepsin B, they saw that HCQ caused cathepsin B staining to change
from being contained in lysosomes to being diffuse throughout the cell. They also concluded that
HCQ causes mitochondrial membrane permeabilization and apoptosis. Boya et al. conducted their
research in HeLa cells and also used some concentrations of HCQ which were higher than the
concentrations used in this study (up to 60 µg/ml). They also did not measure LMP through a
digitonin lysosomal permeability assay measuring NAG, but instead used microscopy to determine
if LMP was occurring; therefore, it is hard to make direct comparisons between their research and
the research presented in this paper (Patricia Boya et al., 2003).
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The above in vitro results were predicated on the assumption that HCQ was being taken up into
lysosomes. In order to test whether HCQ was becoming sequestered into the lysosomes, BMDM
and AM were treated with LysoTracker. HCQ treatment reduced the amount of LysoTracker in
lysosomes of both BMDM in vitro and AM in vivo. These results are consistent with HCQ
sequestration into the lysosomes of these cells. The most likely mechanism by which HCQ is
preventing the uptake of LysoTracker is due to HCQ increasing the pH of the lysosomes.
Additionally, flow cytometry side scatter data from in vitro and in vivo experiments also confirmed
that HCQ was not affecting the ability of cells to phagocytize the cSiO2 particles; therefore, the
toxicity results were not due to changes in cell interactions with particles.

Mice treated with HCQ in vivo showed modest reductions in cSiO2-induced toxicity. Overall,
LDH, total cathepsins, cathepsin B, IFN-g and TNF-a trended lower in HCQ treated mice (Fig.
11-13). It was surprising that cSiO2-induced increase in IL-1b in lung lavage fluid was not blocked
in vivo by HCQ treatment; however, ex vivo culture of the AM from these same studies did result
in significantly less IL-1b release in mice treated with HCQ. Several factors could have been
responsible for the fact that there was not as pronounced of an effect in vivo as there was in vitro.
It is possible that the dosing strategy and exposure time were not sufficient. Additionally, twentyfour hours may be too short of a time to see differences in the immune response. While these
results could indicate that the dose of HCQ was simply too low, the ex vivo results suggest that
there was enough HCQ sequestered into the lysosomes to block inflammasome formation and IL1b production. The results from the ex vivo experiment may be explained by two differences: 1)
the AM were primed for inflammasome activation with LPS when they were plated and 2) they
were incubated for 24 hours in culture after isolation following in vivo cSiO2 exposure. LPS
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stimulates the NF-𝜅B pathway increasing formation of the pro-form of IL-1b and increases the
expression of NLRP3 inflammasome proteins (Sayan & Mossman, 2016). Therefore, it could be
proposed that HCQ blocked IL-1b release by acting on the NF-kB pathway as previously proposed
(X. Chen et al., 2017). In their studies, they pre-treated BMDM with chloroquine before adding
LPS and saw a reduction of phospho-NF-𝜅B p65 protein levels in chloroquine-treated cells.
However, in the in vitro experiments in this study LPS was added prior to HCQ treatment thereby
allowing activation of the NF-kB pathway by LPS to proceed prior to any potential inhibition by
HCQ. Since, there was still a reduction in IL-1b production, it supports the notion that the action
of HCQ to block IL-1b is not at NF-kB but rather at blocking LMP.

Previous research from our laboratory has shown that the tricyclic antidepressant, imipramine, was
able to decrease cSiO2-induced toxicity in vitro and in vivo (Biswas et al., 2017). Because HCQ
and IMP are both lysosomotropic drugs that sequester in lysosomes, we hypothesized that they
would have a similar ability to protect lysosomes from cSiO2-induced LMP. The imipramine study
showed similar results as HCQ in the ability to prevent IL-1β production in vitro and in an ex vivo
culture. IMP was also able to decrease IL-1b levels in the lavage fluid in vivo after a 24-hour
cSiO2 exposure, which was not seen with HCQ. In long-term exposure studies, IMP-treated mice
had less lung pathology and hydroxyproline levels. It is unknown whether other CADs may have
similar protective effects on lysosomal membrane stability after particle exposure and further work
should be done to better understand the interactions between CAD and cSiO2 exposure. To our
knowledge, no other work has been done linking a pharmaceutical intervention with the ability to
block cSiO2-induced LMP.
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Chapter 5: Conclusions and Further Directions
The results of this study support the hypothesis that HCQ can prevent lysosomal membrane
permeability from exposure to cSiO2. The in vitro data strongly suggests that HCQ attenuates
activation of the NLRP3 inflammasome and is doing this, at least in part, by blocking LMP. Cell
death after cSiO2 exposure was decreased with HCQ treatment in vitro. HCQ was able to block the
production of IL-1β and the release of NAG into the cytosol in cSiO2-exposed BMDM indicating
that LMP was being prevented. This was the first study to show that HCQ is able to block LMP.
While the in vivo data is less definitive, it also indicates that HCQ may be protective against cSiO2
toxicity in vivo. These studies were able to confirm that HCQ is accumulating in lysosomes of AM
when mice are treated with HCQ by gavage for 7 days. Data also indicated that HCQ was not
affecting AM’s ability to phagocytize cSiO2 particles. LDH, total cathepsins, and cathepsin B, IFNg, and TNF-a levels trended lower in HCQ-treated mice. Increasing the power of the study by
including more mice would improve the reproducibility of the studies and clarify these differences.
It was surprising that the increase in cSiO2-induced increase of IL-1b in the lung lavage fluid was
not blocked in vivo by HCQ treatment; however, ex vivo culture of the AM did result in
significantly less IL-1b release in mice that were treated with HCQ.

This study was limited by the short time-frame for the in vivo studies. Mice in this study were
sacrificed 24 hours after cSiO2 exposure in order to assess the acute inflammatory response;
however, this time frame is too short to observe histological changes in the lungs. Future studies
would benefit from longer-term exposures to discern if HCQ is able to block the development of
fibrosis and cSiO2-induced pulmonary pathology. Additionally, the dosage and treatment
schedules were determined based on previous literature; however, in order to see more profound
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effects from HCQ, it could be beneficial to increase the dose or lengthen the treatment period (X.
Chen et al., 2017; Gómez-Guzmán et al., 2014). Additionally, this study only assessed the ability
of HCQ to block cSiO2 toxicity by pre-treating cells or mice with HCQ before exposure to cSiO2.
While it is beneficial to have options for prophylactic treatment for individuals who know they
will be exposed to cSiO2, such as military personnel deployed to arid regions, most treatments for
cSiO2 inhalation occur after an exposure has occurred. Therefore, it would be important to conduct
further studies that examine the ability of HCQ to block cSiO2-induced lung injury after exposure.

A large number of workers are exposed to airborne cSiO2 which can contribute to the development
of pulmonary and systemic disease. It is increasingly being recognized that lysosomes are
important modulators of disease; however, there are virtually no pharmaceuticals directed at a
lysosomal mechanism of disease. Many pharmaceuticals become sequestered in the lysosome
through an ion-trapping mechanism, yet this has been considered an undesirable side-effect of the
drugs. The data in this study show HCQ can prevent LMP induced by cSiO2 by accumulating in
lysosomes. It is unknown if other CAD have similar effects on lysosomal membrane stability, and
examining the ways that these drugs interact with lysosomal membranes may provide insight into
their ability to be used as treatments for inhaled particle exposures. Further work should be done
to elucidate the how pharmaceuticals affecting lysosomes may be used to treat diseases caused by
inhaled particles.
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